Christian served as VP and Physician Executive for Bravo Health, the mid-1990’s, venture backed start-up that established the national model for risk-bearing provider groups, and was a progenitor of evidence-based medical practice and personalized healthcare.The company’s 0M acquisition was a testament to the validity and scalability of the clinical model designed, authored, implemented, and managed under “dr Phil’s” guidance.Frank Diehl has over 10 years of experience in assay development in the field of oncology and genomics.He obtained his postdoctoral experience at The Johns Hopkins University and the Howard Hughes Medical Institute in Baltimore, Maryland.Currently, Michael is an independent management consultant in the Life Sciences area. XPhilip Christian, MD, ASCP, ASEM Fellow, American Board of Medical Quality American Society of Clinical Pathology American Society of Emergency Physicians Phil Christian is a successful physician, healthcare executive, serial entrepreneur, and angel investor.Clinically trained in Emergency Medicine and Primary Care, Dr.He led until 2014 the R&D as well as Laboratory Operations of Sysmex Inostics.
Applicants must develop a product or service in (at least) one of the five supported life science segments: Digital Health, Medical Devices, Diagnostics, Therapeutics, or Platform Technologies.Thomas holds an MA in Economics and was a Fulbright Scholar at the American University, Washington D. He also earned a Master in Telecommunications Network Engineering in Paris, France before receiving his Ph. in Telecommunications Economics from University of Stuttgart, Germany.XChristoph Lengauer CEO of German Accelerator Life Sciences Christoph is executive vice president at Blueprint Medicines (BPMC) in Cambridge, MA.GALS then invites selected promising companies to an in-person workshop for a further assessment of their technology and business strategy.XMichael Bogenstaetter Member of GALS Selection Committee Michael Bogenstaetter has over 15 years experience in Biopharma R&D and commercialization of innovative therapies having worked in different leadership roles with companies such as Johnson & Johnson, Novartis and Sanofi and having advised leading Biopharma organizations as member of the Health Care practice of The Boston Consulting Group. in organic chemistry from University of Munich and a full time MBA from London Business School.An abbreviated list of certifications and memberships include: American College of Physician Executives, American College of Healthcare Executives, American College of Medical Practice Executives, American Society of Emergency Medicine, National Association of Managed Care Physicians, National Association of Health Services Executives, and The Society of Physician Entrepreneurs.XFrank Diehl Member of GALS Selection Committee Frank Diehl is currently the Chief Scientific Officer of the Sysmex Life Science Business.The stage of the company’s growth is relevant; the age of the company is not.The GALS application consists of around 20 questions about your company, team, technology, and business plan. We also request that companies submit additional materials with their application, such as a slide deck and a product demo (if available).Companies apply to the GALS program via the external platform Survey Monkey.GALS accepts companies into the program on a rolling basis. Applications are reviewed by the Selection Committee every 6-8 weeks. Next application deadline: February 5, 2018 The GALS Selection Committee meets approximately every 6-8 weeks to evaluate new applications.